Neoplasms

Digestive System Diseases

All Conditions

Gland and Hormone Related Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Esophageal Neoplasms

Adenocarcinoma

Pancreatic Neoplasms

Liver Neoplasms

Adenocarcinoma of Lung

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Esophageal Cancer

Pancreatic Cancer

Biliary Tract Cancer

Lung Adenocarcinoma

new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma

TEG indices

Tracey MacDermott, BA BS CCRC

Ivan Rodriguez, MD

Marco Del Chiaro, MD

The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.

Aim 1: Evaluate the correlation between pre-operative TEG parameters and disease burden in patients with a new diagnosis of hepatopancreaticobiliary, esophageal, colorectal, and lung adenocarcinoma vs controls with no known malignancy.

Aim 2: Explore if pre- and post-operative TEG parameters vs routine clinical coagulation parameters (platelet count, prothrombin time \[PT\], partial thromboplastin time \[PTT\]) are predictive of pre- and post-operative thrombotic (deep vein thrombosis \[DVT\], pulmonary embolism \[PE\], stroke, myocardial infarct \[MI\]) and hemorrhagic complications.

Aim 3: Evaluate if correction of TEG parameters after surgery is predictive of curative resection and if the failure of TEG parameters to correct after surgery or chemoradiothearpy is predictive of cancer recurrence and overall survival.

Aim 4: Perform proteomic analyses on the tumor microenvironment of cancer tissue samples to investigate whether tumor histology and protein composition is associated with specific TEG derangements that have been previously correlated to poor outcomes, potentially identifying a specific subtype of pancreatic cancer.

Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

Use of Viscoelastic Assays Beyond Coagulation: Pre- and Post-operative TEG

R time (minutes \~ coagulation factors), angle (degrees \~ fibrinogen function), MA (mm \~ platelets function), and LY30 (%\~ fibrinolysis) measured at baseline (initial presentation or time of diagnosis), after neoadjuvant chemotherapy (if applicable), pre-operatively (before the induction of general anesthesia), intra-operatively (after tumor removal), post-operative days 1, 3 and 5, and at routine follow up appointments at 2 weeks, 3 months, 6 months and 1 year after surgery.

Disease burden as measured by TNM staging

Pre-operative thrombotic and hemorrhagic complications.

Proteomic analysis of intro-operative sample tumor microenvironment

Post-operative thrombotic and hemorrhagic complications

Number of patients withblood transfusion requirements

Number of patients withpre-operative distant metastasis

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection	NCT05517811	Liver Cancer Esophageal Canc... Colorectal Canc... Lung Adenocarci... Control Pancreas Cancer Biliary Cancer	TEG indices	18 Years - 99 Years	University of Colorado, Denver
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection	NCT05517811	Liver Cancer Esophageal Canc... Colorectal Canc... Lung Adenocarci... Control Pancreas Cancer Biliary Cancer	TEG indices	18 Years - 99 Years	University of Colorado, Denver

Spots Global Cancer Trial Database for teg indices

Every month we try and update this database with for teg indices cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for teg indices

Every month we try and update this database with for teg indices cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for teg indices cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.